Combinatorial biomarkers: From early toxicology assays to patient population profiling

Advanced biomarkers for improved prediction and monitoring of disease and toxicology mechanisms are needed to control the high clinical failure rates among new compounds. Along with other uses, biomarkers are currently used in the industry to screen for toxic side effects of drug candidates and to identify appropriate patient populations. The use of combinatorial biomarkers is a first step towards an effective systems biology approach to drug development. In combination with high content screening, and in particular a novel, high content in situ proteomic technology, combinatorial biomarkers will strongly support the knowledge-based decision-making process by providing crucial information on functional biology.